Ani Pharmaceuticals (ANIP) Accounts Payables (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Accounts Payables data on file, last reported at $69.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 31.35% year-over-year to $69.7 million; the trailing twelve-month figure through Mar 2026 stood at $69.7 million (up 31.35% YoY), and the FY2025 full-year result was $62.6 million, up 37.08% from the prior year.
• Accounts Payables improved to $69.7 million in Q1 2026, from $62.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $69.8 million in Q3 2025 to a low of $19.0 million in Q3 2022.
• A 5-year average of $43.8 million and a median of $45.7 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables jumped 113.0% in 2022 and advanced 3.13% in 2023, its largest moves.
• Tracing ANIP's Accounts Payables over 5 years: stood at $29.3 million in 2022, then advanced by 25.18% to $36.7 million in 2023, then rose by 24.46% to $45.7 million in 2024, then soared by 37.08% to $62.6 million in 2025, then grew by 11.36% to $69.7 million in 2026.
• Business Quant data shows ANIP's Accounts Payables at $69.7 million in Q1 2026, $62.6 million in Q4 2025, and $69.8 million in Q3 2025.